Amkay Products (AMKAY) Q4 FY26 Profit Crashes 78% as Costs and Mix Bite
The healthcare supplier's Q4 FY26 profit fell sharply despite higher annual sales, as a shift to low-margin traded goods and rising costs eroded profitability.
Amkay Products' Q4 FY26 profit plunged 78% year-on-year to ₹0.34 crore, with margins collapsing. A strategic shift towards lower-margin traded goods and higher raw material costs drove the sharp decline, overshadowing full-year revenue growth.
For Amkay Products, a supplier of everyday medical disposables, the final quarter of FY26 revealed a painful trade-off. The company grew its annual sales but saw profitability evaporate, as a strategic pivot and cost pressures converged.
The numbers show a steep sequential decline. Revenue fell 17% from the previous quarter to ₹19.02 crore. Profit collapsed 83% to just ₹0.34 crore, dragging the net profit margin down to 1.8%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr), Q4 FY24: 16.69
Revenue (₹ Cr), Q2 FY25: 17.84
Revenue (₹ Cr), Q4 FY25: 20.55
Revenue (₹ Cr), Q2 FY26: 23.01
Revenue (₹ Cr), Q4 FY26: 19.02
Profit (₹ Cr), Q4 FY24: 1.33
Profit (₹ Cr), Q2 FY25: 1.83
Profit (₹ Cr), Q4 FY25: 1.51
Profit (₹ Cr), Q2 FY26: 1.97
Profit (₹ Cr), Q4 FY26: 0.34
Revenue (₹ Cr)
Revenue (₹ Cr), Q4 FY24: 16.69
Revenue (₹ Cr), Q2 FY25: 17.84
Revenue (₹ Cr), Q4 FY25: 20.55
Revenue (₹ Cr), Q2 FY26: 23.01
Revenue (₹ Cr), Q4 FY26: 19.02
Profit (₹ Cr)
Profit (₹ Cr), Q4 FY24: 1.33
Profit (₹ Cr), Q2 FY25: 1.83
Profit (₹ Cr), Q4 FY25: 1.51
Profit (₹ Cr), Q2 FY26: 1.97
Profit (₹ Cr), Q4 FY26: 0.34
Net Profit Margin
Net Profit Margin, Q4 FY24: 8.0%
Net Profit Margin, Q2 FY25: 10.3%
Net Profit Margin, Q4 FY25: 7.3%
Net Profit Margin, Q2 FY26: 8.6%
Net Profit Margin, Q4 FY26: 1.8%
Metric
CurrentQ4 FY26
Same quarter LYQ4 FY25
Revenue (₹ Cr)
19.02YoY -7.4%
20.55
Profit (₹ Cr)
0.34YoY -77%
1.51
Net Profit Margin
1.8%YoY -75%
7.3%
The Shift to Thin-Margin Sales
The core issue is a changing business mix. According to analysis from Newboard, traded goods—products bought and resold—earn much thinner margins than items made in-house. Their share of sales rose sharply in FY26, which the company cites as a main reason profit fell while sales grew. This structural shift diluted overall margins.
Compounding this, raw material costs surged. A MarketsMojo alert noted that raw material inflation was a key driver behind a massive 88% profit crash in the subsequent half-year. Competitive pricing pressure in a crowded market for simple disposables left little room to pass these costs on.
A Weaker Cushion and Strained Capital
Other income, which provided a cushion in past years, halved in FY26 to about ₹0.7 crore according to the annual report. This removed a support for the bottom line. Meanwhile, working capital efficiency deteriorated.
Live Chart
· AMKAY
(BSE)
ISIN: INE0QSB01016
Inventory days stretched to 125 in FY26, up from 113 the year before. The cash conversion cycle extended to 139 days, indicating more capital is tied up in the business. While annual operating cash flow was positive at ₹1.18 crore, it represented only 31% of the operating profit.
The Path Ahead Looks Challenging
The strain continued into the new fiscal year. For H1 FY27, Amkay reported flat revenue of ₹23 crore but a 90% plunge in net profit to ₹0.23 crore, as per Alfafinder. The operating margin contracted to just 1.7%, suggesting the margin pressure is persistent.
Management is focusing on adding distributors in underserved markets, as noted in the FY26 annual report. A capacity expansion funded by IPO proceeds is also on track for Q4 FY27. However, in a market where price often decides sales, restoring profitability remains the critical test.
Key Points
Q4 FY26 net profit plunged 77.5% year-on-year to ₹0.34 crore, with the net margin collapsing 550 basis points.
A significant increase in low-margin traded goods sales and rising raw material costs drove the severe profitability squeeze.
Working capital intensity increased, with inventory days rising to 125 and the cash conversion cycle extending to 139 days.
Early H1 FY27 results show the pressure continuing, with profit down 90% on flat revenue.
“
Hexa Perspective
Amkay's quarter underscores the vulnerability of a distributor-model pivot without pricing power. The margin compression from traded goods is structural, not cyclical, and raw material inflation adds a persistent headwind. The sharply extended cash conversion cycle signals rising capital needs, which the IPO-funded working capital was meant to address. With profitability at multi-quarter lows and H1 FY27 showing no respite, the turnaround hinges on reversing the margin dilution—a tough ask in a commodity-like market for medical disposables.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Amkay Products' Q4 FY26 results?
Amkay Products reported a Q4 FY26 revenue of ₹19.02 crore, down 7.4% year-on-year. Net profit fell sharply by 77.5% to ₹0.34 crore. The net profit margin contracted to 1.8%, a drop of 550 basis points from the same quarter last year.
Why did Amkay Products' Q4 FY26 profit drop?
Amkay Products' Q4 profit plunged due to a shift towards lower-margin traded goods and rising raw material costs. Analysis from Newboard indicates the increased share of traded goods, which carry thinner margins, was a primary reason profit fell despite annual sales growth.
What was Amkay Products' net profit margin in Q4 FY26?
Amkay Products' net profit margin was 1.8% in Q4 FY26. This represents a severe contraction of 680 basis points from the previous quarter (Q2 FY26) and 550 basis points from the year-ago quarter (Q4 FY25).
Why did Amkay Products' other income fall in Q4 FY26?
Amkay Products' other income fell by 52.5% year-on-year in Q4 FY26. According to the company's FY26 annual report, other income for the full year was about ₹0.7 crore, roughly half the ₹1.3 crore recorded in FY25, contributing to the decline in overall profit.
What is the status of Amkay Products' working capital?
Amkay Products' working capital efficiency deteriorated in FY26. Inventory days increased to 125 from 113, and the cash conversion cycle extended to 139 days. The company's annual report notes that working capital needs have risen, tying up more cash in the business.
What is Amkay Products' order book status as of March 2026?
Amkay Products does not have a traditional order book. The company supplies a wide range of medical disposables through a dealer network, and as noted by Newboard, it operates without a backlog, relying on recurring purchases from hospitals, clinics, and homes.
Is Amkay Products undertaking any capacity expansion?
Yes, Amkay Products has a capacity expansion project underway. According to a MarketsMojo alert, a 31 lakh-unit expansion funded by IPO proceeds is on track to go live in Q4 FY27, in line with timelines set in the company's prospectus.
How did Amkay Products' stock price react to the Q4 FY26 results?
Specific post-results reaction data isn't detailed, but the stock faced pressure in the months surrounding the announcement. Data from Lax.sh shows the stock price was at ₹52.00 at the end of March 2026, down 17.2% from the previous month.
Amkay Products H1 FY27 results?
Amkay Products reported H1 FY27 revenue of ₹23.0 crore, flat compared to H1 FY26. Net profit crashed 90% year-on-year to ₹0.23 crore, as reported by Alfafinder, with the operating margin contracting severely to 1.7%.
Why did Amkay Products profits plunge despite sales growth?
Amkay Products' profits plunged despite annual sales growth due to a damaging mix shift and cost inflation. The company increased its share of low-margin traded goods, and raw material costs surged, compressing margins in a highly competitive market for medical disposables.